Dhipatimendi rePasi Pose

Musi wa21 Kurume, 2025, Junshi Biosciences yakazivisa kuti National Medical Products Administration ("NMPA") yabvumidza kushandiswa kwemushonga mutsva ("sNDA") wemushonga wekambani, toripalimab, pamwe chete nebevacizumab pakurapa mushonga usingabvisike kana kuti une utachiona...Verenga zvakawanda»

Musi wa21 Kurume, 2025, yakazivisa kuti New Drug Application (“NDA”) yeTAZVERIK® (tazemetostat) yakapihwa mvumo muChina yekurapa varwere vakuru vane relapse or refractory (“R/R”) follicular lymphoma (“FL”) vane EZH2 mutation avo vakamboongororwa kaviri kare ...Verenga zvakawanda»

Musi wa10 Kurume, 2025, Sichuan Kelun-Biotech akazivisa kuti mushonga weKambani we trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, yaimbonzi SKB264/MK-2870) wakatenderwa kutengeswa neNational Medical Products Administration (NMPA...Verenga zvakawanda»

Musi wa18 Kurume, 2025, Alphamab Oncology yakazivisa kuti anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 yakapihwa Breakthrough Therapy Designation neCenter for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA). Chitupa ichi ndechekurapa ...Verenga zvakawanda»

Musi wa10 Kurume, 2025, Hansoh Pharma yakazivisa kuti New Drug Application yechitatu ("NDA") yemushonga mutsva weBoka weAmeile (阿美乐®) (Aumolertinib Mesilate Tablets) yakatenderwa neNational Medical Products Administration of China ("NMPA") yekurapa varwere vane chirwere chemuno,...Verenga zvakawanda»

Musi wa12 Kurume, 2025, Zai Lab Limited yakazivisa kuti National Medical Products Administration (NMPA) yeChina yakagamuchira Biologics License Application (BLA) yeTIVDAK (tisotumab vedotin-tftv) yekurapa varwere vane kenza yemumuromo inodzoka kana kuti yakapararira nechirwere ichi...Verenga zvakawanda»

Musi wa5 Kurume, 2025, Ascentage Pharma yakazivisa kuti mushonga wayo, olverembatinib, wakapihwa Breakthrough Therapy Designation (BTD) neCenter for Drug Evaluation (CDE) yeChina's National Medical Products Administration (NMPA), nekuda kwekusanganiswa ne low-intensity chemotherapy pakurapwa kwekutanga...Verenga zvakawanda»

Musi wa4 Kurume, 2025, BeiGene yakazivisa kuti US Food and Drug Administration (FDA) yabvumidza TEVIMBRA(tislelizumab-jsgr), pamwe chete ne platinum-containing chemotherapy, yekurapa kwekutanga kwevanhu vakuru vane unrepactable kana metastatic esophageal squamous cell carcinoma (ESCC) vane ...Verenga zvakawanda»

Musi wa25 Kukadzi, 2025, National Medical Products Administration (NMPA) yeChina yakabvumidza finotonlimab pamwe chete neSCT510 yekurapa chirwere chehepatocellular carcinoma chisingabvisike kana kuti chisati chamborapwa. Finotonlimab iIgG4 inosanganiswa nevanhu...Verenga zvakawanda»

Musi wa8 Kukadzi, 2025, National Medical Products Administration (NMPA) yeChina yakabvumidza mushonga weSinocelltech Group Ltd wefinotonlimab, mushonga we programmed-death 1 (PD-1) monoclonal antibody (mAb), kuti ushandiswe pamwe chete ne platinum-based chemotherapy senzira yekutanga yekurapa zvirwere zvinodzokorora uye/kana metastases...Verenga zvakawanda»

Musi wa21 Kukadzi 2025, Center for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yeChina yakapa Breakthrough Therapy Designation (BTD) yeSatri-cel (CT041) (chigadzirwa cheCAR T-cell chinoonekwa sechinoda Claudin18.2), chechirwere chemudumbu/esophagogastric jun...Verenga zvakawanda»

Musi wa22 Kukadzi, 2025, New Drug Application (NDA) yekubaiwa ipirimumab (anti-CTLA-4 monoclonal antibody; R&D Code: IBI310) yakagamuchirwa neCenter for Drug Evaluation (CDE) yeChina's National Medical Products Administration (NMPA) uye yakapihwa Priority Review in com...Verenga zvakawanda»